We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
24 Jan 2022 - 27 Jan 2022

Global Lateral Flow Assay Market to Reach Nearly USD 6.5 Billion by 2031 Due to Surge in Demand for Rapid POC Testing

By LabMedica International staff writers
Posted on 01 Dec 2021
Print article

The global lateral flow assay market is projected to grow at a CAGR of around 5% from USD 3.7 billion in 2020 to over USD 6.4 billion by 2031, driven by the growing adoption of home-based lateral flow assay kits, demand growth of point-of-care testing, and rise in adoption of LFA kits due to their advantages over laboratory tests.

These are the latest findings of Persistence Market Research (New York City, NY, USA), a third-party research organization.

Lateral flow assays are mainly used for diagnostics for home testing, laboratory use, and point-of-care testing. The most widely applied and well-known applications of lateral flow assays are home pregnancy tests. The rising prevalence of infectious diseases is a key growth driver of the lateral flow assay market. The emergence of diseases such as coronavirus, Zika virus, Ebola, and others has increased the procurement of point-of-care testing devices and kits by international bodies such as UNICEF. Furthermore, the current COVID-19 pandemic has boosted the demand for lateral flow tests. COVID-19 infections are diagnosed with lateral flow assay-based tests across the world.

Mobile phones provide rapid results in real time, saving time and reducing result reporting delays. They also allow users to record the time and results of a test. Further, easy and cost-effective sharing of data along with cloud integration has resulted in better centralization and analysis of data using online information sharing platforms. This technology enables clinicians or patients in remote areas to image samples that can be used for TB and malaria diagnosis.

By product, LFA kits will hold a high share of 70% of the lateral flow assay market in 2021 and is expected to record a mid-single digit CAGR during the forecast period, led by rising adoption of products in this segment that offer ease of use, low cost, and ease of production. By indication, infectious disease is expected to hold a market share of well over 50% in 2021 and continue growing at a moderate rate in line with the increasing prevalence of infectious diseases globally. The high adoption of point-of-care testing for quick diagnosis at hospitals has led to hospital pharmacies holding a high market share. By region, North America held nearly 1/3 of the global market share in 2021, mainly due to a rise in health care expenditures, increasing adoption of lateral flow assays, and the presence of prominent players in the region.

"Although the COVID-19 pandemic boosted market growth in 2020, it is expected to be a temporary phase. However, developments such as smartphone-based readers for LFA will continue to provide fruitful growth opportunities for market players over the coming years," stated an analyst at Persistence Market Research.

Related Links:
Persistence Market Research

Gold Supplier
Nucleic Acid Extraction System
POC Clinical Chemistry Analyzer
Automatic Urine Sediment Analyzer
Automated Nucleic Acid Extraction & Purification System
ExiPrep16 Dx

Print article
IIR Middle East


Molecular Diagnostics

view channel

Point-of-Care Lateral Flow Test Detects Bladder Cancer Using Urine Sample within Minutes

A breakthrough diagnostics platform uses a multiplexed lateral flow assay that detects 10 bladder cancer biomarkers from a urine sample in either laboratory or point-of-care settings. SCIENION (Berlin,... Read more


view channel
Image: Bone marrow aspirate from a patient with Acute Myeloid Leukemia: Blasts are the predominant population and have a high nuclear to cytoplasmic ratio and generally lack granules. (Photo courtesy of Professor Peter G. Maslak, MD)

Cord Blood and Matched Related Donor Transplantation Compared in Acute Myeloid Leukemia

The prognosis of primary refractory and relapsed acute myeloid leukemia is poor, with a five-year overall survival of less than 10%. Allogeneic hematopoietic stem cell transplantation (HSCT) is the only... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.